Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Experimental biology and medicine

• Publication date

  2010-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1258/ebm.2010.010203PMID 20975079
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Imiquimod Enhances IFN-γ Production and Effector Function of T Cells Infiltrating Human Squamous Cell Carcinomas of the Skin

  2011cited by this paper
• Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin.

  2009cited by this paper
• Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.

  2009cited by this paper
• Dependence on Nuclear Localization Signals of the Opioid Growth Factor Receptor in the Regulation of Cell Proliferation

  2009cited by this paper
• Imiquimod, a Toll-like receptor 7 agonist, inhibits melanogenesis and proliferation of human melanocytes.

  2009cited by this paper
• The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation.

  2009cited by this paper
• In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod‐treated basal cell carcinoma

  2009cited by this paper
• Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis1

  2009cited by this paper
• The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer

  2008cited by this paper
• Imiquimod Upregulates the Opioid Growth Factor Receptor to Inhibit Cell Proliferation Independent of Immune Function

  2008cited by this paper
• Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells.

  2007cited by this paper
• The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer.

  2007cited by this paper
• Imiquimod: mode of action

  2007cited by this paper
• Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas

  2006cited by this paper
• Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod

  2006cited by this paper
• Opioids and differentiation in human cancer cells.

  2005cited by this paper
• Imiquimod Treatment Induces Expression of Opioid Growth Factor Receptor

  2004cited by this paper
• Psoriasis induced by topical imiquimod

  2004cited by this paper
• Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod.

  2003cited by this paper
• Opioids and the apoptotic pathway in human cancer cells.

  2003cited by this paper
• Topically applied imiquimod inhibits vascular tumor growth in vivo.

  2003cited by this paper
• Imiquimod; an international update on therapeutic uses in dermatology

  2002cited by this paper
• The biology of the opioid growth factor receptor (OGFr).

  2002cited by this paper
• The opioid growth factor, [Met5]‐enkephalin, inhibits DNA synthesis during recornification of mouse tail skin

  2000cited by this paper
• Imiquimod applied topically: a novel immune response modifier and new class of drug.

  1999cited by this paper
• The opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor are present in human and mouse skin and tonically act to inhibit DNA synthesis in the epidermis.

  1996cited by this paper

• In vitro anti-melanoma activity of imiquimod in ultradeformable nanovesicles

  2022cites this paper
• The role of topical imiquimod in melanoma cutaneous metastases: A critical review of the literature

  2020cites this paper
• The uses of naltrexone in dermatologic conditions.

  2019cites this paper
• Targeting B Cell Acute Lymphoblastic Leukemia with Oncolytic Virotherapy and Histone Deacetylase Inhibition

  2014cites this paper
• TLR7 signaling exacerbates CNS autoimmunity through downregulation of Foxp3+ Treg cells

  2014cites this paper
• Opioid Antagonists Enhance Diabetic Wound Closure: A New Therapy

  2014cites this paper
• Low dose naltrexone (LDN) enhances maturation of bone marrow dendritic cells (BMDCs).

  2013cites this paper
• Penile Intraepithelial Neoplasia: Successful Treatment with Topical 5% Imiquimod Cream

  2012cites this paper
• Modulation of the opioid growth factor ([Met5]‐enkephalin)–opioid growth factor receptor axis: Novel therapies for squamous cell carcinoma of the head and neck

  2012cites this paper
• Endogenous opiates and behavior: 2010.

  2011cites this paper
• Targeting opioid signaling in Crohn’s disease: new therapeutic pathways

  2011cites this paper
• T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.

  2011cites this paper